Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of ONC-392 versus docetaxel in metastatic squamous non-small cell lung cancer after progression on PD-1/PD-L1 inhibitor plus platinum chemotherapy
CTR20232927Phase 3Active
- Sponsor
- OncoImmune
- Start
- Oct 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gotistobart, docetaxel in non-small cell lung cancer (NSCLC), Pulmonary squamous cell carcinoma, sponsored by OncoImmune. Started Oct 2023; status: active.
02
Drugs
gotistobartdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20232927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232927.